

Assessment of *in situ*-Prepared Polyvinylpyrrolidone-Silver Nanocomposite for Antimicrobial Applications

W. EL HOTABY^a, H.H.A. SHERIF^{a,*}, B.A. HEMDAN^b, W.A. KHALIL^c, S.K.H. KHALIL^a

^aSpectroscopy Department, Physics Division, National Research Center, Cairo, Egypt

^bEnvironmental Microbiology Lab, Water Pollution Research Department, National Research Center, Cairo, Egypt

^cBiophysics Department, Faculty of Science, University of Cairo, Cairo, Egypt

(Received March 13, 2017; in final form April 14, 2017)

Polyvinylpyrrolidone (PVP) is employed in several potential applications, relying of its special chemical and physical properties in addition to its low toxicity and biocompatibility. The aim of this work is to prepare polyvinylpyrrolidone-silver (PVP-Ag) nanocomposite with high inhibiting effect on the microbial growth and low cytotoxicity. *In situ* prepared small stable spherical silver nanoparticles, with narrow range particle size distribution, were obtained by easy, economical and rapid chemical reduction method. Silver ions were reduced to silver nanoparticles using low amount of sodium borohydride (NaBH₄) as a strong reducing agent. PVP-Ag nanocomposite was prepared using PVP as a stabilizing and capping agent. Formation of the spherical silver nanoparticles with mean particle size 5 nm was confirmed by ultraviolet-visible spectroscopy, high resolution transmission electron microscopy, and dynamic light scattering. The inhibiting growth effect of the nanocomposite toward Gram-positive bacteria (*Staphylococcus aureus*), Gram-negative bacteria (*Pseudomonas aeruginosa*), and yeast fungus (*Candida albicans*) were studied. The cytotoxicity of the nanocomposite against BJ1 normal skin fibroblast cell line was tested. Results of this work presented perfect antimicrobial activity of the PVP-Ag nanocomposite towards bacteria and fungi with low cytotoxicity, which may lead to promising applications in skin wound healing.

DOI: [10.12693/APhysPolA.131.1554](https://doi.org/10.12693/APhysPolA.131.1554)

PACS/topics: silver nanoparticles, polyvinylpyrrolidone, nanocomposite, antimicrobial activity, cytotoxicity

1. Introduction

In both hospitals and community-acquired infections, the antimicrobial resistance has reached a crisis point, since it became an affecting public health factor throughout the world [1]. The microbial resistance to antibiotics is referred to the fact that the majority of these antibiotics are targeting intercellular components without any effect on the cellular morphology. Therefore, many researchers have been working on developing macromolecular antimicrobial materials that perform the microbial membrane disruption to the microbial membrane; consequently, developed resistance through cell mutation can be avoided [2]. As soon as an individual is attacked by multidrug resistance bacteria (MRD), it is not easy to treat and more time is taken in the hospital. Although this requires high cost treatments with broad spectrum antibiotics, it still has low effectiveness and high toxicity. Thus, it is a priority area of research to develop or modify antimicrobial compounds improving bactericidal potential [3].

For long period of time, different chemical forms of silver have been accepted as effective antimicrobial agents which are highly active against bacteria, viruses and fungi [4–6]. However, a decline in silver medical applications as antimicrobial occurred due to the progress of antibiotics [3, 7, 8]. After that, the era of nanotechnology was

emerged (1–100 nm) carrying highly promising properties of the silver for medical applications. At nanoscale, the ultra-small particle size brings about ultra-large surface area per mass therefore direct contact with ambience is achieved by large number of atoms which are readily available for reaction [8, 9]. AgNPs have specific properties such as high thermal conductivity and stability [10], and strong shape-dependent optical properties [11, 12]. Furthermore, AgNPs are capable of enhancing the scarless wound healing and cosmetic appearance [13, 14]. Moreover, AgNPs are considered as one of the most inorganic materials [15].

A variety of preparation methods, namely physical [16], chemical [17], biosynthetic [18] and biological [19, 20] approaches have been studied to prepare AgNPs. The solution and solid state AgNPs could be produced by photochemical synthesis [21], laser ablation [22], microwave treatment [23] and γ -irradiation [24]. The reduction of AgNPs in such physical techniques depends mainly on the supplied activation energy through thermal heating, laser irradiation, ultrasonic, fixed frequency microwave radiation, UV irradiation [25]. On the other hand, the synthesis of AgNPs by biosynthetic and biological methods through the interaction of plant extract, bacteria, fungi, actinomycetes and algae has been widely explored [26]. Although physical and biological approaches have been established to be an alternative to conventional methods, the chemical methods are still more versatile [9].

It is believed that better control of size, shape and monodispersity will lead to enhancement of AgNPs

*corresponding author; e-mail: hhasherif@yahoo.com

production with high precision which would be applied in the various fields [26]. Fortunately, chemical reduction method is chosen to be applied due to its advantages of being rapid, simple and economical way to produce AgNPs with well-controlled size and shape, using reducing and stabilizing agents to prevent these nanoparticles from agglomeration [9]. A soluble silver salts (either in water or organic solvent) is reduced by any of the reducing agents as citrate, ethyl glycol, glucose, or sodium borohydride [27]. Christy et al. [28] prepared Ag NPs by chemical reduction method using *N,N*-dimethylformamide and PVP under ultrasonic field. In chemical reduction method, the redox potential, temperature, concentration of the reactants and additions, and the solvent properties used are controlling factors in the size and particle distribution as well as the antimicrobial activity of produced nanoparticles. Using strong reducing agents (such as NaBH_4) initiate high reduction rate leading to fast releasing of atoms in the saturated solution. As a consequence, much more nucleation rate occurs at the expense of the particles growth rate. Thus, small monodispersed nanoparticles are obtained and vice versa [29–31]. Addition of stabilizers as natural and synthetic polymers to metal components, using different methods, is used to prevent the coalescence of the nanoparticles [17]. Also, the production of a very narrow particle size distribution with uniformity can be expected. Polymers with certain affinity toward metals such as chitin, chitosan [32] polyvinyl alcohol, polyacrylamide, acrylonitrile, and PVP, are the most used substance for metal nanoparticles stabilization [12]. Considerable attention is drawn to PVP owing to its special chemical and physical properties recommending it as a coating or as additive to different materials [6]. PVP can perform a dual role: first is stability and second is controlling the rate of silver ions reduction and aggregation process of silver atoms [6, 33]. Moreover, low toxicity and acceptable biocompatibility make PVP suitable and promising for medical applications [31].

Consequently, the objective of this work is to prepare PVP–Ag nanocomposite with stable and small AgNPs with narrow particle size distribution for the antimicrobial activity against bacteria and fungi. *In situ* reduction of AgNPs in room temperature (without any activation energy) using chemical reduction method can be utilized. We also aim to study the optimum condition of the reaction, such as the amount of NaBH_4 and AgNO_3 solution by using UV-vis spectroscopy. Low amounts of the strong reducing agent NaBH_4 can be employed, to decrease the cytotoxicity of the nanocomposite assisting it as a biomedical material. A precise antimicrobial test (colony counting method) and cytotoxicity toward BJ1 normal skin fibroblast cell line can be used.

2. Materials and methods

2.1. Materials

Polyvinylpyrrolidone PVP (molecular biology grade) ($\text{C}_6\text{H}_9\text{NO}$)_n with average F.M. 40,000 was purchased

from Fisher, USA. L-ascorbic acid L-A.A. ($M = 176.13$) from ACS. Sodium borohydride fine granules NaBH_4 (98%) was purchased from Merck (Russian Fed.), and silver nitrate AgNO_3 extra pure was from SRL (India). Milli-Q water was used during the sample preparation. All the purchased chemicals were used without further purification.

2.2. Methods

100 μL of L-A.A. solution of 0.01 M was added to 5 ml PVP solution (2 wt%). The mixture was stirred for 10 min then X - μL of AgNO_3 solution (0.01 mol/L) was added to the solution under stirring, where $X = 10, 30, 50, 70, 100$ μL . After that Y - μL of NaBH_4 solution (0.1 M) was added to the mixture and stirred for 15 min, where $Y = 10$ to 70 μL . The color of the solution turned yellow immediately. For film formation, certain amount of the nanocomposite solution was casted in the Petri dish and dried at 60 °C.

2.3. Characterization

Synthesis of AgNPs was initially confirmed by using UV-vis spectroscopy. The absorption spectra were recorded in the range between 200 nm and 800 nm using spectrophotometer Jasco V-630, India. The Fourier transform infrared (FTIR) spectra were recorded by BRUKER-VERTEX 70 (Germany) using KBr disc method. X-ray diffraction (XRD) measurement were carried out by X-ray diffraction X'Pert Pro PANalytical (Holland), targeted by Cu_{α} with secondary monochromator (45 kV, 40 mA). The morphological structure (size and shape) of AgNPs is studied using high resolution transmission electron microscope HRTEM (JEOL-2100). The particle size distribution and zeta potential of the AgNPs stabilized and capped by PVP were characterized by dynamic light scattering (DLS) using a Malvern nano ZS (Malvern instrument Ltd., Worcestershire, UK).

2.4. Inhibition of microbial growth

2.4.1. Microorganisms used and preparation

Three strains (*Staphylococcus aureus* ATCC6538, *Pseudomonas aeruginosa* ATCC15442 and *Candida albicans* ATCC10231) were cultured in tryptic soya broth (Oxoid-UK) and incubated at 37 °C for 24 h. After the incubation, the suspensions were homogenized by the vortex and centrifuged at 3000 rpm for 20 min and washed three times by adding sterile phosphate buffered solution. The density of each strain inocula was 10^6 CFU/ml.

2.4.2. Cell viability test

The antimicrobial effect PVP–Ag nanocomposite was determined against three different microbial strains. The stock suspension of each bacterial strain was previously prepared. Each one of the stock suspension was exposed to four concentrations of PVP–Ag (25, 50, 75, and 100 $\mu\text{g}/\text{mL}$) at three contact times (60, 90, and 120 min). Cells of *S. aureus*, *P. aeruginosa* and *C. albicans* were incubated with PVP–Ag nanocomposite in distilled water

at 37 °C under 250 rpm shaking speed. The viability of each tested strains cells was evaluated by the colony counting method according to (APHA, 2012). Colonies were counted, and compared to those on control plates to calculate changes in the cell growth inhibition. All treatments were prepared in duplicate and repeated at least on three separate occasions.

2.5. MTT cytotoxicity test

Cytotoxicity of PVP–AgNPs composite was determined by Cell proliferation kit1 (MTT assay) for non-radioactive quantification of cell proliferation and cell viability based on succinate-tetrazolium reductase (Bio Basic Canada Inc., Canada). This enzyme is capable of reducing tetrazolium dye MTT to formazan, turning the color from yellow to purple. A sterile laminar air flow cabinet biosafety class II level (Baker, SG403INT, Stanford, ME, USA) was used for performing all the preceding steps. Cells were incubated in humidified 5% CO₂ incubator at 37 °C (Sheldon, TC2323, Cornelius, OR, USA). Approximately, BJ1 (normal Skin fibroblast) cells were seeded in 96-well μ L plastic plates and kept for 24 h to adhere. After that, media was aspirated and various concentrations (from 100 to 0.78 μ g/mL) of the composite were added to the cells. The cells were then incubated for another 48 h. Media was aspirated and for each well, 40 μ l MTT salt (2.5 μ g/mL) were added and incubated for further 4 h. For stopping the reaction and dissolving any formed formazan crystals, 200 μ L of sodium

dodecyl sulfate (10%) was added and incubated overnight at 37 °C. The formazan amount produced was measured using a microplate reader (Bio-Rad Laboratories, model 3350, USA) at wavelength 595 nm with a background reference of 620 nm. As a negative control, wells containing only the cells were used. Whereas the positive control, known as cytotoxic natural agent giving 100% inhibition, used was Adrinamycin® (doxorubicin) ($M_r = 579.9$). Dimethyl sulfoxide (DMSO) was used for dissolution of the tested compounds.

3. Results and discussion

3.1. Ultraviolet-visible spectroscopy

Investigating the effect of different volumes of AgNO₃ and NaBH₄ solutions in preparation of AgNPs under constant environmental conditions was carried out by UV-vis spectroscopy. It was observed that the color of the mixture changed from colorless to yellow which was considered as the first evidence for the AgNPs formation. Figure 1a–g displays the UV-vis absorption spectra of PVP–Ag nanocomposites prepared with different volumes of NaBH₄ (10, 20, 30, 40, 50, 60, and 70 μ L), respectively. The PVP–Ag nanocomposite spectra of all samples exhibited a single characteristic surface plasmon resonance (SPR) absorption band around 410 nm which indicates the formation of AgNPs. The appearance of a single absorption band in the range 400–450 nm suggests that the AgNPs is formed in spherical shape [34–37].




Fig. 1. UV-vis absorption spectra of PVP–Ag nanocomposites prepared with different volumes of NaBH₄ (a)–(g) solutions added to specific volumes of 10–100 μ L of AgNO₃ solution.

It also can be noticed that the intensity of SPR band of AgNPs increases with increasing the volume of AgNO₃ solution (Fig. 1). For the samples prepared using 100 μ L of AgNO₃ solution, the SPR band Fig. 1a–d showed broadening toward longer wavelength, whereas

Fig. 1e–g showed symmetrical and narrow shape of SPR band. It can be concluded that using little amount of NaBH₄ (10–40 μ L) solution relative to that of AgNO₃ (100 μ L) solution tends to produce polydispersed AgNPs, while adequate amount (50–70 μ L) produced spherical

monodispersed AgNPs. This is in consistence with Tran et al. [38], who suggested that prepared AgNPs, using chitosan as reducing agent, were spherical and monodispersed according to the symmetrical and narrow shape of SPR band.

For further examination, the absorbance of the SPR band was drawn as a function of the volume of AgNO_3 solution (Fig. 2). It can be observed that for all specified volumes of NaBH_4 solutions under investigation, the absorbance increases with increase of the volume of AgNO_3 solution till it reaches maximum at 100 μL of AgNO_3 . The lowest rate of absorbance rise is seen for nanocomposites prepared using 10 and 20 μL of NaBH_4 solution at 100 μL AgNO_3 solution. This result concedes with that reported by Song et al. [10]. Based on the UV-vis results, the ratio between amounts of 10 μL NaBH_4 to 50 μL AgNO_3 was optimized for further investigations.




Fig. 2. Effect of the volume of AgNO_3 solution on the intensity of the produced PVP–Ag nanocomposite SPR band.

3.2. X-ray diffraction

The XRD pattern of pure PVP (Fig. 3a) showed two broad characteristic peaks at 2θ of 11.25° and 21.21° corresponding to d -values of 7.7826 and 4.1844 \AA , respectively. This is in good agreement with results reported by Li et al. [39]. The XRD pattern of PVP–Ag nanocomposite film showed two 2θ of 10.77° and 21.61° corresponding to d -values of 8.2129 and 4.3096 \AA , respectively. This finding can be due to the very low concentration (0.01 M) and amount (50 μL) of the AgNO_3 used in the composite preparation, in one hand, and the PVP masking to the nanoparticles, in the other hand.

3.3. Fourier transform infrared spectroscopy

Figure 4a,b represents FTIR spectra of PVP and PVP–Ag nanocomposite, respectively. The spectra showed a broad band at 3441 cm^{-1} due to OH stretching vibration. A medium peak and a weak shoulder appeared at 2955 cm^{-1} and 2893 cm^{-1} , respectively, which are corresponding to symmetric and asymmetric stretching vibrations of CH_2 , respectively [40, 41]. A strong




Fig. 3. X-ray diffraction pattern of: (a) pure PVP, (b) PVP–Ag nanocomposite film (prepared by 50 μL of AgNO_3 solution and 10 μL of NaBH_4 solution).

sharp peak ascribed to C=O stretching vibration appeared at 1663 cm^{-1} [42, 43], followed by four medium peaks at 1495 , 1462 , 1439 , and 1423 cm^{-1} which could be assigned to scissoring vibration of CH_2 group. CH_2 wagging vibrations and C–N stretching appeared at 1318 cm^{-1} and 1290 cm^{-1} , respectively [44, 45]. CH_2 twisting and rocking vibrations appeared at 1229 cm^{-1} and 1018 cm^{-1} . Comparing with PVP spectrum, the spectrum of PVP–Ag nanocomposite (Fig. 4b) showed no change in the spectral features which may be due to the small amount of AgNPs present in the sample. This observation supports the results obtained from XRD.




Fig. 4. FTIR spectra of (a) PVP, (b) PVP–Ag nanocomposite (prepared by 50 μL of AgNO_3 solution and 10 μL of NaBH_4 solution).

3.4. High resolution-transmission electron microscopy

The HRTEM was used to study the morphological structure (size and shape) of the AgNPs in freshly prepared sample of PVP–Ag nanocomposite (Fig. 5a).




Fig. 5. HRTEM analysis: (a) image of PVP–Ag nanocomposite (prepared by 50 μL of AgNO_3 solution and 10 μL of NaBH_4 solution), (b) particle size distribution of AgNPs in PVP–Ag nanocomposite with Gaussian fitting curve, (c) image of particle crystallinity of AgNPs, and (d) diffraction pattern of the AgNPs.

The AgNPs are very small, spherical and loosely distributed in the polymer. The histogram shown in Fig. 5b represents the particle size distribution analyzed in the TEM micrograph (Fig. 5a) by revolution 4pi-Analysis-v1.6.0b195 program. It exhibits narrow range of particle size distribution (2–8 nm), with mean value and standard deviation of 4.92 ± 1.38 nm, and polydispersity index (PDI) 0.279 indicating particles monodispersity. The crystalline structure of AgNPs is shown in Fig. 5c. The diffraction of AgNPs is shown in Fig. 5d.

3.5. Particle size distribution and zeta potential

Particle size distribution of AgNPs was measured by DLS (Z -average) and found to be 5.6 ± 1.4 nm as shown in Fig. 6. In order to insure the accuracy of the results, the particle size distribution and PDI of the nanocomposite were analyzed again by DLS. The mean particle size of DLS is larger than $\approx 14\%$ the particle size measured by HRTEM. The obtained results by DLS were compared to those obtained from HRTEM and listed in Table I. However, the DLS depends on the hydrodynamic size while HRTEM depends on the physical size. Thus, the DLS bias tends to larger size fractions [46]. The dispersity is the measure of the heterogeneity of particles' sizes in the medium. The PDI calculated is 0.334 which clarifies monodispersity of nanoparticles [47]. Zeta potential was determined for PVP–Ag nanocomposite and found to be -2.88 mV. However, NPs were well-dispersed in the composite (as shown in the TEM micrographs) in spite of their low zeta potential. This is may be attributed to the stabilizing effect of the large molecular

weight of PVP to AgNPs through steric stabilization as mentioned by Elbaz et al. [48]. The AgNPs produced by reduction via the NaBH_4 are stabilized by the capping effect of PVP. The capping mechanism can be interpreted in terms of the hydrophilic amide groups and the hydrophobic vinyl groups of the PVP. The AgNPs are tied up with the amide groups of PVP through their strong affinity of N and O atoms for transition metals. In the same time, the hydrophobic vinyl backbone surrounds the AgNPs to prevent their aggregations. Therefore, PVP plays an important role in controlling the shape and size of AgNPs [24].




Fig. 6. Dynamic light scattering size distribution graph of the AgNPs.

TABLE I

Comparison between HRTEM and DLS for AgNPs as indicated by the mean particle size (nm), standard deviation (S.D.) and the polydispersity index (PDI).

Test	Mean [nm]	S.D. [d.nm]	PDI
HT-TEM	4.922	1.375	0.279
DLS	5.618	1.427	0.334

3.6. Inhibition of microbial growth

The effect of PVP–Ag nanocomposite (100 $\mu\text{g}/\text{mL}$) on the bacterial and fungal growth was examined for different contact times (1, 1.5, 2, 3 h). The nanocomposite showed 100% elimination of the microorganisms with 100 $\mu\text{g}/\text{mL}$ and shaking 250 rpm and represented in Table II. Four different concentrations of the nanocomposite were examined at 2 h contact time towards the bacterial and fungal growth. The results are listed in Table III. Surprisingly, all Gram-positive, Gram-negative and fungus were totally killed even by using minimum concentration of the nanocomposite (25 $\mu\text{g}/\text{mL}$).

Few studies have reported the antimicrobial activity of PVP–AgNPs by determining minimal inhibitory concentration (MIC) values against *S. aureus*, *P. aeruginosa* and *C. albicans*. In comparison to other studies, our results show superior antimicrobial activity. Bhati et al. [20] determined the MIC values of PVP coated AgNPs with particle size 10–30 nm (prepared by biological method) against *S. aureus* and *P. aeruginosa* as 46 $\mu\text{g}/\text{mL}$

and against *C. albicans* as 23 $\mu\text{g}/\text{mL}$. Dey et al. [49] evaluated the MIC value of PVP-AgNPs with particle size 54 nm against *S. aureus* as 67.41 $\mu\text{g}/\text{mL}$. Crespo et al. [15] prepared PVP-AgNPs with mean particle size 4.8 ± 3.0 nm whereas larger particles between 7 nm and 25 nm were found in a lesser amount. The MIC values of PVP-Ag NPs against *S. aureus* and *P. aeruginosa* were evaluated as 100 $\mu\text{g}/\text{mL}$ and 200 $\mu\text{g}/\text{mL}$, respectively.

TABLE II

Effect of different contact times with the nanocomposite (100 $\mu\text{g}/\text{mL}$) on the bacterial and fungal growth.

Bacterial strain	Contact time [h]			
	1	1.5	2	3
<i>Pseudomonas aeruginosa</i> (4.2×10^6 CFU/ml)	ND	ND	ND	ND
<i>Staphylococcus aureus</i> (3.7×10^6 CFU/ml)	ND	ND	ND	ND
<i>Candida albicans</i> (5.3×10^6 CFU/ml)	ND	ND	ND	ND

TABLE III

Effect of different concentrations at contact time (2 h) on the bacterial and fungal growth.

Bacterial strain	PVP-Ag nanocomposite doses [$\frac{\mu\text{g}}{\text{mL}}$]			
	25	50	75	100
<i>Pseudomonas aeruginosa</i> (6.2×10^6 CFU/ml)	ND	ND	ND	ND
<i>Staphylococcus aureus</i> (4.6×10^6 CFU/ml)	ND	ND	ND	ND
<i>Candida albicans</i> (3.4×10^6 CFU/ml)	ND	ND	ND	ND

3.7. Cytotoxicity

Cytotoxicity was investigated against BJ1 cell line after 48 h of incubation with the nanocomposite. The cells cytotoxicity was 18.5%, which demonstrate the biocompatibility behavior of the nanocomposite.

4. Conclusion

PVP-Ag nanocomposite with uniform monodispersed stabilized spherical AgNPs (≈ 5 nm) was synthesized by simple, economical and rapid reduction method using NaBH_4 and PVP. PVP helped controlling the nanoparticles size and distribution through its capping and stabilizing effects, preventing the agglomeration and precipitation of the nanoparticles. Interestingly, 100% elimination of the Gram-positive, Gram-negative bacteria, and fungi were detected using as low as 25 $\mu\text{g}/\text{mL}$ concentration of the nanocomposite prepared beside its biocompatibility behavior toward BJ1 normal cells. Finally, this work is considered as a first step for production of low cost bandages for wound burn treatment and all of the provided studies are complementary to future work.

Acknowledgments

This work was funded by Science and Technology Development Fund STDF (grant number 12645).

Compliance with ethical standards and conflicts of interest

The research carried out within this work did not involve human participants and/or animals. The authors declare that they have no conflict of interest.

References

- [1] R. Cristescu, A. Visan, G. Socol, A.V. Surdu, A.E. Oprea, A.M. Grumezescu, M.C. Chifriuc, R.D. Boehm, D. Yamaleyeva, M. Taylor, R.J. Narayan, D.B. Chrisey, *Appl. Surf. Sci.* **374**, 290 (2016).
- [2] V.W.L. Ng, J.M.W. Chan, H. Sardon, R.J. Ono, J.M. Garcia, Y.Y. Yang, J.L. Hedrick, *Adv. Drug Deliv. Rev.* **78**, 46 (2014).
- [3] M.K. Rai, S.D. Deshmukh, A.P. Ingle, A.K. Gade, *J. Appl. Microbiol.* **112**, 841 (2012).
- [4] V.K. Sharma, R.A. Yngard, Y. Lin, *Adv. Coll. Interface Sci.* **145**, 83 (2009).
- [5] I. Sonidi, B. Salopek-Sonidi, *J. Coll. Interface Sci.* **275**, 177 (2004).
- [6] R. Bryaskova, D. Pencheva, S. Nikolov, T. Kantardjiev, *J. Chem. Biol.* **4**, 185 (2011).
- [7] J.J. Castellano, S.M. Shafii, F. Ko, G. Donate, T.E. Wright, R.J. Mannari, W.G. Payne, D.J. Smith, M.C. Robson, *Int. Wound J.* **4**, 114 (2007).
- [8] X. Chen, H.J. Schluesener, *Toxicol. Lett.* **176**, 1 (2008).
- [9] P. Van Dong, C.H. Ha, L.T. Binh, J. Kasbohm, *Int. Nano Lett.* **2**, 9 (2012).
- [10] K.C. Song, S.M. Lee, T.S. Park, B.S. Lee, *Kor. J. Chem. Eng.* **26**, 153 (2009).
- [11] Q. Zhang, N. Li, J. Goebel, Z. Lu, Y. Yin, *J. Am. Chem. Soc.* **133**, 18931 (2011).
- [12] E. Silva, S.M. Saraiva, S.P. Miguel, J.I. Correia, *J. Nanopart. Res.* **16**, 2726 (2014).
- [13] Y.A. Krutyakov, A.A. Kudrinskiy, A.Y. Olenin, G.V. Lisichkin, *Russ. Chem. Rev.* **77**, 233 (2008).
- [14] D. Pencheva, R. Bryaskova, T. Kantardjiev, *Mater. Sci. Eng. C* **32**, 2048 (2012).
- [15] J. Crespo, J. Garcia-Barrasa, J.M. Lopez-de-Luzuriaga, M. Monge, M.E. Olmos, Y. Saenz, C. Torres, *J. Nanopart. Res.* **14**, 1281 (2012).
- [16] N.A. Zulina, I.M. Pavlovetc, M.A. Baranov, V.O. Kaliabin, I.Y. Denisyuk, *Appl. Phys. A* **123**, 39 (2017).
- [17] Z. Zhang, B. Zhao, L. Hu, *J. Solid State Chem.* **121**, 105 (1996).
- [18] A.K. Singh, R. Tiwari, V. Kumar, P. Singh, S.K. Riyazat Khadim, A. Tiwari, V. Srivastava, S.H. Hasan, R.K. Asthana, *J. Photochem. Photobiol. B Biol.* **166**, 202 (2017).
- [19] A. Kushwaha, V.K. Singh, J. Bhartariya, P. Singh, K. Yasmeen, *Eur. J. Exp. Boil.* **5**, 65 (2015).
- [20] D. Bhatia, A. Mittal, D.K. Malik, *3 Biotech.* **6**, 196 (2016).
- [21] K. Mallick, M.J. Witcomb, M.S. Scurrrell, *J. Mater. Sci.* **39**, 4459 (2004).
- [22] N.A. Zulina, I.M. Pavlovetc, M.A. Baranov, I.Y. Denisyuk, *Opt. Laser Technol.* **89**, 41 (2017).

- [23] O.S. Oluwafemi, T. Mochochoko, A.J. Leo, S. Mohan, D.N. Jumbam, S.P. Songca, *Mater. Lett.* **185**, 576 (2016).
- [24] Ž. Jovanović, A. Krklješ, S. Tomić, V. Mišković-Stanković, S. Popović, M. Dragašević, Z. Kačarević-Popović, in: *Trends in Nanophysics*, Series *Engineering Materials*, Eds. V. Barsan, A. Aldea, 2010, p. 315.
- [25] H. Jiang, K.-S. Moon, Z. Zhang, S. Pothukuchi, C.P. Wong, *J. Nanopart. Res.* **8**, 117 (2008).
- [26] K. Sahayaraj, S. Rajesh, in: *Sci. Against Microb. Pathog. Commun. Curr. Res. Technol. Adv.*, Ed. A. Méndez-Vilas, 2011, p. 228.
- [27] S. Chernousova, M. Epple, *Angew. Chem. Int. Ed.* **52**, 1636 (2013).
- [28] A.J. Christy, A. Kevin, L.C. Nehru, M. Umadevi, *Int. J. Chem. Tech. Res.* **7**, 1191 (2015).
- [29] D.V. Goia, *J. Mater. Chem.* **14**, 451 (2004).
- [30] C. Marambio-Jones, E.M.V. Hoek, *J. Nanopart. Res.* **12**, 1531 (2010).
- [31] O. Lyutakov, Y. Kalachyova, A. Solovyev, S. Vytykacova, J. Svanda, J. Siegel, P. Ulbrich, V. Svorcik, *J. Nanopart. Res.* **17**, 120 (2015).
- [32] M.A. Moharram, S.K.H. Khalil, H.H.A. Sherif, W.A. Khalil, *Spectrochim. Acta Part A Mol. Biomol. Spectrosc.* **126**, 1 (2014).
- [33] H. Huang, Q. Yuan, X. Yang, *Coll. Surf. B Biointerfaces* **39**, 31 (2004).
- [34] O. Choi, K.K. Deng, N.J. Kim, L. Ross, R.Y. Surampalli, Z. Hu, *Water Res.* **42**, 3066 (2008).
- [35] G.A. Martínez-Castanón, N. Nino-Martínez, F. Martínez-Gutierrez, J.R. Martínez-Mendoza, F. Ruiz, *J. Nanoparticle Res.* **10**, 1343 (2008).
- [36] Y.-K. Twu, Y.-W. Chen, C.-M. Shih, *Powder Technol.* **185**, 251 (2008).
- [37] D. Wei, W. Sun, W. Qian, Y. Ye, X. Ma, *Carbohydr. Res.* **344**, 2375 (2009).
- [38] H.V. Tran, L.D. Tran, C.T. Ba, H.D. Vu, T.N. Nguyen, D.G. Pham, P.X. Nguyen, *Coll. Surf. A Physicochem. Eng. Asp.* **360**, 32 (2010).
- [39] X.G. Li, I. Kresse, J. Springer, J. Nissen, Y.L. Yang, *Polymer* **42**, 6859 (2001).
- [40] Y. Sun, X. Wang, Y. Lu, L. Xuan, S. Xia, W. Feng, X. Han, *Chem. Res. Chin. Univ.* **30**, 703 (2014).
- [41] J.R. Mohanty, S.N. Das, H.C. Das, S.K. Swain, *Fibers Polym.* **15**, 1062 (2014).
- [42] C.M. Laot, E. Marand, H.T. Oyama, *Polymer* **40**, 1095 (1999).
- [43] B. Liang, Y. Xie, Z. Fang, E.P. Tsang, *J. Nanopart. Res.* **16**, 2485 (2014).
- [44] H.-D. Wu, I.-D. Wu, F.-C. Chang, *Polymer* **42**, 555 (2001).
- [45] M.T. Ansari, V.B. Sunderland, *Arch. Pharm. Res.* **31**, 390 (2008).
- [46] S.A. Cumberland, J.R. Lead, *J. Chromatogr. A* **1216**, 9099 (2009).
- [47] K. Dziendzikowska, J. Gromadzka-Ostrowska, A. Lankoff, M. Oczkowski, A. Krawczyńska, J. Chwastowska, M. Sadowska-Bratek, E. Chajduk, M. Wojewódzka, M. Dušínská, M. Kruszewski, *J. Appl. Toxicol.* **32**, 920 (2012).
- [48] N.M. Elbaz, L. Ziko, R. Siam, W. Mamdouh, *Nat. Publ. Gr.* **6**, 30729 (2016).
- [49] A. Dey, A. Dasgupta, V. Kumar, A. Tyagi, A. Kamra Verma, *Int. Nano Lett.* **5**, 223 (2015).